Compare IRMD & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | DBVT |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2014 | 2014 |
| Metric | IRMD | DBVT |
|---|---|---|
| Price | $101.41 | $21.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.75 |
| AVG Volume (30 Days) | 51.0K | ★ 292.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $73,242,121.00 | $4,151,000.00 |
| Revenue This Year | $11.99 | $1,768.71 |
| Revenue Next Year | $9.91 | $1,028.88 |
| P/E Ratio | $80.71 | ★ N/A |
| Revenue Growth | ★ 11.71 | N/A |
| 52 Week Low | $47.48 | $3.82 |
| 52 Week High | $107.90 | $26.19 |
| Indicator | IRMD | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 51.48 |
| Support Level | $92.51 | $20.25 |
| Resistance Level | $106.42 | $25.52 |
| Average True Range (ATR) | 3.59 | 1.35 |
| MACD | 0.09 | -0.25 |
| Stochastic Oscillator | 46.05 | 31.00 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.